Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ERA 2026

European Renal Association (ERA) - 63rd Congress - 2026

June 03 - 06, 2026

  1. All
  2. Chronic Kidney Disease
  3. Hypertension
  4. Hyperkalaemia
  5. Diabetes
  6. Systemic Lupus Erythematosus
  7. Farxiga (dapagliflozin)
  8. Lokelma (sodium zirconium cyclosilicate)
  9. Heart Failure
  10. Chronic Kidney Disease & Diabetes

HTML

Acute changes in eGFR during treatment with balcinrenone and dapagliflozin: An Exploratory Analysis of the MIRO-CKD trial

HTML

Detecting hidden CKD in hypertension: Diagnostic yield of adding uACR to eGFR in primary care (NyreSPOT)

HTML

Incidence and prevalence of chronic kidney disease: a Scottish population-based cohort study

HTML

Mind the (treatment) gap: eligibility versus prescribing in core therapies for chronic kidney disease

HTML

Moderate albuminuria as the main entry point to incident chronic kidney disease detection in routine care: results from the OPTIMISE-CKD study

HTML

Assessing the magnitude of win statistics and study design considerations for the kidney hierarchical composite endpoint

HTML

Real-world evidence on blood pressure control in patients with chronic kidney disease in Germany: alignment of treatment with elevated disease risk

HTML

CKD care across comorbidity profiles: claims-based insights by diabetes and heart failure status

HTML

Economic evaluation of SGLT2 inhibitor for the management of chronic kidney disease in the Danish healthcare system

HTML

Strength of association and validation of surrogate endpoints in chronic kidney disease: a systematic literature review

PDF

Prevalence of albuminuria across glomerular filtration rate categories in chronic kidney disease: a systematic review

PDF

Validity of linear eGFR slopes for predicting kidney failure: a RESET CKD patient-level simulation across pivotal CKD trials

HTML

Mineralocorticoid receptor antagonist initiation in cardiorenal patients: hyperkalaemia and discontinuation by kidney function in the CaRe study

PDF

Design and baseline characteristics of the ZENITH High Proteinuria trial: zibotentan/dapagliflozin efficacy on chronic kidney disease progression

PDF

Use of a screening study to accelerate participant enrolment in clinical trials: lessons from the ZENITH High Proteinuria trial

PDF

Baxdrostat/dapagliflozin chronic kidney disease program: design and rationale

PDF

Combined zibotentan/dapagliflozin shows a well-described and competitive clinical pharmacology profile, supporting broad usage in proteinuric CKD

HTML

Detecting hidden CKD in hypertension: Diagnostic yield of adding uACR to eGFR in primary care (NyreSPOT)

HTML

Kidney disease progression in inadequately controlled hypertension despite dual antihypertensive therapy: a large population-based cohort study

HTML

Real-world evidence on blood pressure control in patients with chronic kidney disease in Germany: alignment of treatment with elevated disease risk

HTML

Timing of normokalaemia recovery after hyperkalaemia: association with patient characteristics, initial management and healthcare resource utilisation

HTML

Distribution of renal function at recruitment by sex and drug class in phase 3/4 type 2 diabetes mellitus trials

HTML

Burden of disease in SLE patients with renal affection

HTML

Characteristics of patients with chronic kidney disease using dapagliflozin in real-life settings in Central Eastern Europe: OPTIMISE-CKD CEE study

HTML

Dapagliflozin for chronic kidney disease with/without type 2 diabetes: patient's profile in Central Eastern Europe (OPTIMISE-CKD CEE real-world study)

HTML

HK management trends over 12 months in a Spanish cohort: Insights from the prospective TRACK Study

HTML

Clinical profile, hyperkalemia management and persistence in Sodium Zirconium Cyclosilicate initiators in Spain by baseline potassium levels: the VITALIZE real world study

HTML

Characterization and management of hyperkalaemia in real-world clinical practice: insights from HYPER K+, a multicentric observational study in Portugal

HTML

Mineralocorticoid receptor antagonist initiation in cardiorenal patients: hyperkalaemia and discontinuation by kidney function in the CaRe study

PDF

Proteinuria testing patterns in primary care patients with chronic kidney disease: results from England and the USA in the observational PROMISE study

HTML

Acute changes in eGFR during treatment with balcinrenone and dapagliflozin: An Exploratory Analysis of the MIRO-CKD trial

HTML

Detecting hidden CKD in hypertension: Diagnostic yield of adding uACR to eGFR in primary care (NyreSPOT)

HTML

Incidence and prevalence of chronic kidney disease: a Scottish population-based cohort study

HTML

Mind the (treatment) gap: eligibility versus prescribing in core therapies for chronic kidney disease

HTML

Moderate albuminuria as the main entry point to incident chronic kidney disease detection in routine care: results from the OPTIMISE-CKD study

HTML

Assessing the magnitude of win statistics and study design considerations for the kidney hierarchical composite endpoint

HTML

Real-world evidence on blood pressure control in patients with chronic kidney disease in Germany: alignment of treatment with elevated disease risk

HTML

CKD care across comorbidity profiles: claims-based insights by diabetes and heart failure status

HTML

Economic evaluation of SGLT2 inhibitor for the management of chronic kidney disease in the Danish healthcare system

HTML

Strength of association and validation of surrogate endpoints in chronic kidney disease: a systematic literature review

PDF

Prevalence of albuminuria across glomerular filtration rate categories in chronic kidney disease: a systematic review

PDF

Validity of linear eGFR slopes for predicting kidney failure: a RESET CKD patient-level simulation across pivotal CKD trials

HTML

Mineralocorticoid receptor antagonist initiation in cardiorenal patients: hyperkalaemia and discontinuation by kidney function in the CaRe study

PDF

Design and baseline characteristics of the ZENITH High Proteinuria trial: zibotentan/dapagliflozin efficacy on chronic kidney disease progression

PDF

Use of a screening study to accelerate participant enrolment in clinical trials: lessons from the ZENITH High Proteinuria trial

PDF

Baxdrostat/dapagliflozin chronic kidney disease program: design and rationale

PDF

Combined zibotentan/dapagliflozin shows a well-described and competitive clinical pharmacology profile, supporting broad usage in proteinuric CKD

HTML

Detecting hidden CKD in hypertension: Diagnostic yield of adding uACR to eGFR in primary care (NyreSPOT)

HTML

Kidney disease progression in inadequately controlled hypertension despite dual antihypertensive therapy: a large population-based cohort study

HTML

Real-world evidence on blood pressure control in patients with chronic kidney disease in Germany: alignment of treatment with elevated disease risk

HTML

Timing of normokalaemia recovery after hyperkalaemia: association with patient characteristics, initial management and healthcare resource utilisation

HTML

Distribution of renal function at recruitment by sex and drug class in phase 3/4 type 2 diabetes mellitus trials

HTML

Burden of disease in SLE patients with renal affection

HTML

Characteristics of patients with chronic kidney disease using dapagliflozin in real-life settings in Central Eastern Europe: OPTIMISE-CKD CEE study

HTML

Dapagliflozin for chronic kidney disease with/without type 2 diabetes: patient's profile in Central Eastern Europe (OPTIMISE-CKD CEE real-world study)

HTML

HK management trends over 12 months in a Spanish cohort: Insights from the prospective TRACK Study

HTML

Clinical profile, hyperkalemia management and persistence in Sodium Zirconium Cyclosilicate initiators in Spain by baseline potassium levels: the VITALIZE real world study

HTML

Characterization and management of hyperkalaemia in real-world clinical practice: insights from HYPER K+, a multicentric observational study in Portugal

HTML

Mineralocorticoid receptor antagonist initiation in cardiorenal patients: hyperkalaemia and discontinuation by kidney function in the CaRe study

PDF

Proteinuria testing patterns in primary care patients with chronic kidney disease: results from England and the USA in the observational PROMISE study

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States